This is required for clinical trials that involve blinding, especially when there are risks of serious harm to research subjects.
Blinding is a common strategy used to reduce bias in research.
When a research subject experiences serious injury or harm, it may be necessary to know which drug or intervention they have used. Researchers should have a plan that allows them to ‘break the blind’ quickly for an individual participant without having to do so for everybody else.